Karyopharm shares surge 11.12% premarket after Cantor Fitzgerald initiates Overweight rating citing high-probability SENTRY trial success.

Karyopharm Therapeutics (NASDAQ: KPTI) surged 11.12% in premarket trading following Cantor Fitzgerald’s initiation of coverage with an Overweight rating, citing a 70% probability of success for its Phase 3 SENTRY trial in myelofibrosis. The analyst highlighted selinexor’s potential to reposition the company as a frontline myelofibrosis contender in a $1 billion market, with a $62 per-share fundamental value estimate. Positive momentum was further reinforced by Piper Sandler and RBC Capital maintaining Overweight/Outperform ratings and preliminary 2025 revenue figures showing $145 million in total revenue. While the February 12 earnings report announcement provided a timeline for updates, the premarket rally primarily reflected optimism around Cantor Fitzgerald’s analysis and the anticipated SENTRY trial results in March 2026.